Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, announces it has met the primary endpoint for its Proof of Concept Phase 2a clinical trial of SENS-401 for residual hearing preservation following cochlear implantation.
